SHIFTBIO’s pipeline is aiming to cure orphan diseases and cancer.
Candidate | SBI-101 |
Indication | Immunotherapy resistant |
| |||||||
| |||||||
Candidate | SBI-102 [SIRP-Exo, MSC] |
Indication | NASH with liver Fibrosis |
| |||||||
| |||||||
Candidate | SBI-103 |
Indication | Undisclosed |
| |||||
| |||||
Candidate | SBI-104 |
Indication | Pulmona |
| |||||
| |||||
Candidate | SBI-205 |
Indication | Liver damage |
| |||||
| |||||
Candidate | SBI-306 |
Indication | Immunotherapy |
| |||||
| |||||
Candidate | SBI-407 |
Indication | Undisclosed |
| |||||
| |||||
Candidate | SBI-508 |
Indication | Immunotherapy |
| |||||
| |||||
Candidate | SBI-609, LGP-S01 |
Indication | Undisclosed |
| |||||
| |||||
SHIFTBIO’s pipeline is aiming to cure orphan diseases and cancer.
Candidate | Indication |
| |||||||
SBI-101 [SIRP-Exo] | Immunotherapy resistant |
| |||||||
SBI-102 [SIRP-Exo, MSC] | NASH with liver fibrosis | ||||||||
SBI-103 [EGF-Exo] | Undisclosed |
| |||||||
SBI-104 [Apelin-Exo] | Pulmonary arterial hypertension |
| |||||||
SBI-205 [Exo-HIF1α] | Liver damage | ||||||||
SBI-306 [RSFV-Exo-UP] | Immunotherapy resistant |
| |||||||
SBI-407 [Fc-Exo, MSC] | Undisclosed |
| |||||||
SBI-508 [Ag-Exo] | Immunotherapy resistant |
| |||||||
SBI-609, LGP-S01 [ImmuNano] | Undisclosed |
| |||||||
